B Cell Maturation Antigen Targeted Therapies Market Predicted to Grow at a Moderate Pace Through 2017 - 2025
Middle-aged men who have a past history of monoclonal gammopathy have highest risk of developing multiple myeloma with the exposure of chemicals or radiations. It is important to increase awareness about effective treatment of cancer and related diseases among the research community to provide major restraint for increase in BCMA targeted treatment market in future. Rise in prevalence of multiple myeloma globally is expected to boost the expansion of the BCMA targeted therapies market in the near future. Multiple myeloma can be fatal and can recur with other associated serious complications.
Middle-aged men who have a past history of monoclonal gammopathy have highest risk of developing multiple myeloma with the exposure of chemicals or radiations. It is important to increase awareness about effective treatment of cancer and related diseases among the research community to provide major restraint for increase in BCMA targeted treatment market in future. Rise in prevalence of multiple myeloma globally is expected to boost the expansion of the BCMA targeted therapies market in the near future. Multiple myeloma can be fatal and can recur with other associated serious complications.
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
B-cell m<strong>at</strong>ur<strong>at</strong>ion antigen (BCMA) is a protein, also called tumor necrosis fac<strong>to</strong>r recep<strong>to</strong>r<br />
superfamily member 17 (TNFRSF17) or CD269 antigen, which is encoded in humans by<br />
TNFRSF17 gene. BCMA is an essential member of tumor necrosis fac<strong>to</strong>r recep<strong>to</strong>r super family and<br />
is preferentially expressed in B lymphocytes. B-cell m<strong>at</strong>ur<strong>at</strong>ion antigen recep<strong>to</strong>r is necessary for B-<br />
cell development and also in au<strong>to</strong>immune response. This recep<strong>to</strong>r specially binds <strong>to</strong> tumor necrosis<br />
fac<strong>to</strong>r (TNF) super family member 13b.<br />
BCMA or TNFRSF17 binds <strong>to</strong> TNF and activ<strong>at</strong>es NF-kappaB and MAPK8/JNK. TNFRSF17 also<br />
binds with other TRAF family members and may conduct or transfer signals for cell prolifer<strong>at</strong>ion<br />
and survival. It is a recep<strong>to</strong>r for TALL-1, and activ<strong>at</strong>es NF-kappaB through a NIK-, TRAF5-, IKK-,<br />
and TRAF6- dependent p<strong>at</strong>hway. For TALL-1, TNFRSF17 is identified as NF-kappaB activ<strong>at</strong>ing<br />
recep<strong>to</strong>r by targets for drug development against certain au<strong>to</strong>immune diseases or immunodeficient.<br />
BCMA works as a target of donor B-cell immunity in p<strong>at</strong>ients with myeloma who respond <strong>to</strong> donor<br />
lymphocyte infusions (DLI). BCMA may contribute rejection of tumor in vivo as the response of<br />
antibody <strong>to</strong> the cell surface. Recent study suggests th<strong>at</strong> BCMA is effective against cells with<br />
multiple myeloma (MM). It is a deadly disease of plasma cells, which needs some medi<strong>at</strong>ion by<br />
clinical researchers.<br />
Report Overview and TOC @ https://www.transparencymarketresearch.com/b-cell-m<strong>at</strong>ur<strong>at</strong>ionantigen-targeted-therapies-market.html<br />
Middle-aged men who have a past his<strong>to</strong>ry of monoclonal gammop<strong>at</strong>hy have highest risk of<br />
developing multiple myeloma with the exposure of chemicals or radi<strong>at</strong>ions. It is important <strong>to</strong><br />
increase awareness about effective tre<strong>at</strong>ment of cancer and rel<strong>at</strong>ed diseases among the research<br />
community <strong>to</strong> provide major restraint for increase in BCMA targeted tre<strong>at</strong>ment market in future.<br />
Rise in prevalence of multiple myeloma globally is expected <strong>to</strong> boost the expansion of the BCMA<br />
targeted therapies market in the near future. Multiple myeloma can be f<strong>at</strong>al and can recur with other<br />
associ<strong>at</strong>ed serious complic<strong>at</strong>ions. Prevalence of multiple myeloma and other serious f<strong>at</strong>al diseases<br />
needs specific diagnosis and targeted tre<strong>at</strong>ment <strong>at</strong> the global level. Therefore, there is an immedi<strong>at</strong>e<br />
requirement of effective therapies and medical care, which is likely <strong>to</strong> fuel the expansion of the<br />
BCMA market in near future.<br />
Request Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?<br />
flag=B&rep_id=25505<br />
The global BCMA targeted therapy market can be segmented in<strong>to</strong> product type, end-user, and<br />
region. In terms of product type, the market can be segmented in<strong>to</strong> CAR-T cells, bispecific<br />
antibodies, and antibody drug conjug<strong>at</strong>es. These are the different kind of products rel<strong>at</strong>ed <strong>to</strong> B-cell<br />
m<strong>at</strong>ur<strong>at</strong>ion antigen based on mechanism or function perform with other proteins or cells of body as<br />
identific<strong>at</strong>ion and destruction of tumor cell lysis of malignant multiple myeloma and conjug<strong>at</strong>e<br />
form<strong>at</strong>ion with antibodies. In terms of end-user, the global BCMA targeted therapies market can be<br />
segmented in<strong>to</strong> hospitals and cancer research institutes. In terms of geography, the market can be<br />
segmented in<strong>to</strong> North America, L<strong>at</strong>in America, Europe, Asia Pacific, and Middle East & Africa.<br />
Key players oper<strong>at</strong>ing in the BCMA targeted therapies market are Celgene Corpor<strong>at</strong>ion, Bluebird<br />
Bio, Poseida Therapeutics, Inc., Juno Therapeutics, and Eureka Therapeutics. Several stakeholders<br />
have entered the market for development of novel therapy. They provide funds for research and<br />
development of BMCA targeted therapy in both clinical and commercial research space. Some<br />
clinical stage products th<strong>at</strong> have emerged out of such collabor<strong>at</strong>ions include BCMA-CART<br />
(Abramson Cancer Center of the University of Pennsylvania and Novartis) and bb2121 (Celgene<br />
and Bluebird Bio).
Pre Book Full Report @ https://www.transparencymarketresearch.com/b-cell-m<strong>at</strong>ur<strong>at</strong>ion-antigentargeted-therapies-market.html?secure=NTIxNS41&type=PB<br />
About Us<br />
Transparency <strong>Market</strong> Research (TMR) is a global market intelligence company providing business<br />
inform<strong>at</strong>ion reports and services. The company’s exclusive blend of quantit<strong>at</strong>ive forecasting and<br />
trend analysis provides forward-looking insight for thousands of decision makers. TMR’s<br />
experienced team of analysts, researchers, and consultants use proprietary d<strong>at</strong>a sources and various<br />
<strong>to</strong>ols and techniques <strong>to</strong> g<strong>at</strong>her and analyze inform<strong>at</strong>ion.<br />
TMR’s d<strong>at</strong>a reposi<strong>to</strong>ry is continuously upd<strong>at</strong>ed and revised by a team of research experts so th<strong>at</strong> it<br />
always reflects the l<strong>at</strong>est trends and inform<strong>at</strong>ion. With extensive research and analysis capabilities,<br />
Transparency <strong>Market</strong> Research employs rigorous primary and secondary research techniques <strong>to</strong><br />
develop distinctive d<strong>at</strong>a sets and research m<strong>at</strong>erial for business reports.<br />
Contact<br />
Transparency <strong>Market</strong> Research<br />
St<strong>at</strong>e Tower,<br />
90 St<strong>at</strong>e Street,<br />
Suite 700,<br />
Albany NY - 12207<br />
United St<strong>at</strong>es<br />
Tel: +1-518-618-1030<br />
USA - Canada Toll Free: 866-552-3453<br />
Sales: sales@transparencymarketresearch.com<br />
Website: https://www.transparencymarketresearch.com/<br />
Blog: http://www.tmrblog.com/
Change language